Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects.

Trial Profile

Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexanabinol (Primary)
  • Indications Brain cancer; Glioma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors e-Therapeutics
  • Most Recent Events

    • 09 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Feb 2014 The first patient has been dosed and completion is expected in quarter 4, 2014, according to an e Therapeutics media release.
    • 10 Feb 2014 Status changed from planning to recruiting, as reported by an e Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top